US20180325906A1 - Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties - Google Patents
Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties Download PDFInfo
- Publication number
- US20180325906A1 US20180325906A1 US15/908,373 US201815908373A US2018325906A1 US 20180325906 A1 US20180325906 A1 US 20180325906A1 US 201815908373 A US201815908373 A US 201815908373A US 2018325906 A1 US2018325906 A1 US 2018325906A1
- Authority
- US
- United States
- Prior art keywords
- theobromine
- bone
- salt
- cell
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 title claims abstract description 368
- 229960004559 theobromine Drugs 0.000 title claims abstract description 164
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 81
- 230000001965 increasing effect Effects 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000001605 fetal effect Effects 0.000 title claims abstract description 14
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 8
- 208000021017 Weight Gain Diseases 0.000 title claims description 5
- 230000004584 weight gain Effects 0.000 title claims description 5
- 235000019786 weight gain Nutrition 0.000 title claims description 5
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000011164 ossification Effects 0.000 claims abstract description 17
- 230000007547 defect Effects 0.000 claims abstract description 14
- 230000037182 bone density Effects 0.000 claims abstract description 9
- 210000000845 cartilage Anatomy 0.000 claims abstract description 9
- 208000002925 dental caries Diseases 0.000 claims abstract description 8
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 201000002170 dentin sensitivity Diseases 0.000 claims abstract description 4
- 230000000395 remineralizing effect Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 56
- 239000013078 crystal Substances 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 20
- 230000035935 pregnancy Effects 0.000 claims description 16
- 230000008774 maternal effect Effects 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 12
- 230000002188 osteogenic effect Effects 0.000 claims description 12
- 208000001132 Osteoporosis Diseases 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 230000006651 lactation Effects 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 235000013365 dairy product Nutrition 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 239000003925 fat Substances 0.000 claims description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 6
- 235000014347 soups Nutrition 0.000 claims description 6
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 5
- 108010064851 Plant Proteins Proteins 0.000 claims description 4
- 235000015496 breakfast cereal Nutrition 0.000 claims description 4
- 229940112822 chewing gum Drugs 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000021118 plant-derived protein Nutrition 0.000 claims description 4
- 235000011962 puddings Nutrition 0.000 claims description 4
- 235000012206 bottled water Nutrition 0.000 claims description 3
- 235000011950 custard Nutrition 0.000 claims description 3
- 235000015203 fruit juice Nutrition 0.000 claims description 3
- 235000020351 fruit smoothie Nutrition 0.000 claims description 3
- 235000013613 poultry product Nutrition 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- 235000008924 yoghurt drink Nutrition 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000013332 fish product Nutrition 0.000 claims description 2
- 235000015270 fruit-flavoured drink Nutrition 0.000 claims description 2
- 235000013622 meat product Nutrition 0.000 claims description 2
- 235000020124 milk-based beverage Nutrition 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 235000013322 soy milk Nutrition 0.000 claims description 2
- 235000015192 vegetable juice Nutrition 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- 235000012820 baking ingredients and mixes Nutrition 0.000 claims 1
- 230000008468 bone growth Effects 0.000 abstract description 2
- 244000299461 Theobroma cacao Species 0.000 description 28
- 241000700159 Rattus Species 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 21
- 235000009470 Theobroma cacao Nutrition 0.000 description 20
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 210000000689 upper leg Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 13
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 13
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 13
- 102000046949 human MSC Human genes 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 10
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 10
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 9
- 239000013589 supplement Substances 0.000 description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 8
- 229960001948 caffeine Drugs 0.000 description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 7
- 235000019219 chocolate Nutrition 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000000474 nursing effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100022337 Integrin alpha-V Human genes 0.000 description 6
- 102000008108 Osteoprotegerin Human genes 0.000 description 6
- 108010035042 Osteoprotegerin Proteins 0.000 description 6
- -1 amine salt Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 6
- 210000002303 tibia Anatomy 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000002639 bone cement Substances 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020100 Hip fracture Diseases 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 235000019221 dark chocolate Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000001650 focal adhesion Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 229940001587 tarka Drugs 0.000 description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102100033825 Collagen alpha-1(XI) chain Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100026559 Filamin-B Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000710623 Homo sapiens Collagen alpha-1(XI) chain Proteins 0.000 description 2
- 101000913551 Homo sapiens Filamin-B Proteins 0.000 description 2
- 101000972488 Homo sapiens Laminin subunit alpha-4 Proteins 0.000 description 2
- 102100022743 Laminin subunit alpha-4 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 2
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108010048673 Vitronectin Receptors Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000675 anti-caries Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000014461 bone development Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000020140 chocolate milk drink Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 235000020278 hot chocolate Nutrition 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000003211 trypan blue cell staining Methods 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000019220 whole milk chocolate Nutrition 0.000 description 2
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical class BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BLANYTBRGRAQTP-UHFFFAOYSA-N CN1C=NC2=C1C(=O)N(C)C(=O)N2C.CN1C=NC2=C1C(=O)NC(=O)N2C.[H]N1C=NC2=C1C(=O)N(C)C(=O)N2C Chemical compound CN1C=NC2=C1C(=O)N(C)C(=O)N2C.CN1C=NC2=C1C(=O)NC(=O)N2C.[H]N1C=NC2=C1C(=O)N(C)C(=O)N2C BLANYTBRGRAQTP-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000020849 Class Ia Phosphatidylinositol 3-Kinase Human genes 0.000 description 1
- 108010019804 Class Ia Phosphatidylinositol 3-Kinase Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000584595 Homo sapiens Ras-related protein Rap-1A Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102100030706 Ras-related protein Rap-1A Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100030676 Rho GTPase-activating protein 35 Human genes 0.000 description 1
- 101710110510 Rho GTPase-activating protein 35 Proteins 0.000 description 1
- 102000057028 SOS1 Human genes 0.000 description 1
- 101710146001 Son of sevenless homolog 1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000003650 acai Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000248 cariostatic effect Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000011967 chocolate pudding Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940119429 cocoa extract Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 230000008234 focal adhesion pathway Effects 0.000 description 1
- 235000015219 food category Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000020627 health maintaining nutrition Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000032631 intramembranous ossification Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000010258 osteoblastogenesis Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
Definitions
- the present disclosure relates to compositions and methods for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, or combinations thereof, in a subject in need thereof, improving maternal and/or child health during the stages of preconception, pregnancy, lactation, and/or postpartum, and increasing osteoblastic/osteogenic activity in mesenchymal stem cells (MSCs; also called “marrow stromal cells” or “multipotent stromal cells”). More particularly, said compositions comprise cocoa extract.
- MSCs mesenchymal stem cells
- Theobromine (IUPAC name: 3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; also known as 3,7-dimethylxanthine) is a white (or colorless) bitter-tasting crystalline powder with a sublimation point of 290-295° C., a melting point of 357° C., and a molecular weight of 180.16 g/mol.
- the solubility of theobromine in water is 1.0 g/2 L; in boiling water, it is 1.0 g/150 mL, and in 95% ethanol it is 1.0 g/2.2 L.
- Theobromine is related chemically to caffeine and theophylline, and is found in numerous foods including chocolate, cocoa, tea leaves, and acai berries.
- the chemical structures of theobromine, theophylline (1,3-dimethylxanthine), and caffeine (1,3,7-trimethylxanthine) are given below as formulae I, II, and III, respectively.
- Theobromine is found naturally in cacao beans ( Theobroma cacao ) at a concentration of from about 1.5% to about 3%, and in the husk of the bean at a concentration of from about 0.7% to about 1.2%, or about 15 to about 30 g/Kg (Winholdz, 1983).
- Caffeine acts relatively quickly, and its main effect on humans is increased mental alertness; theobromine's effect is subtler, and causes a mood elevation that is milder longer-lasting than that of caffeine.
- Theobromine's plasma half-life (t 1/2 ) in the bloodstream is six hours, while caffeine's is only two hours. Another difference is that theobromine is not physiologically addictive, producing no withdrawal symptoms after prolonged regular consumption, while caffeine has been proven to be physiologically addictive and linked with many cases of proven withdrawal.
- theobromine refers to theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- Theobromine can also be isolated or produced as an amine salt (e.g., the ethylene diamine salt thereof) or a double salt thereof (e.g., with alkali metal salts or alkaline earth metal salts of organic acids, for example alkali or alkaline earth metal salts of acetic, gluconic, benzoic, or salicylic acid).
- the double salts may be prepared either to make the theobromine more water souble, or to make insoluble complexes.
- Str ⁇ lfors reported a reduction of dental caries in hamsters that were fed diets rich in chocolate.
- the Str ⁇ lfors study examined the effect on hamster caries by comparing cocoa powder, defatted cocoa powder, and cocoa fat. Pure cocoa powder inhibited dental caries by 84%, 75%, 60%, and 42% when the cocoa powder comprised 20%, 10%, 5%, and 2% percent of the hamster diet, respectively.
- Defatted cocoa showed a significantly higher anti-caries effect than did fat-containing cocoa powder, but cocoa butter alone (comprising 15% of the hamster's diet) increased dental caries significantly (Str ⁇ lfors A. “Effect on Hamster Caries by Dialyzed, Detanned or Carbon-treated Water-Extract of Cocoa” Arch OralBiol. 1966; 11:609-15.
- the Hall-Petch relationship dictates that the resistance of a solid material to permanent deformation (e.g., its indentation hardness) increases as the particle size decreases. Consequently, the increased hydroxylapatite crystallinity observed after exposure to theobromine—coupled with the Hall-Petch relationship—suggests that the resistance of bone and teeth to indentation and permanent deformation should decrease after exposure to theobromine due to the larger crystal size.
- This suggestion finds support in recent work, demonstrating that “the hardness of [hydroxylapatite] follows the Hall-Petch relationship as the grain size decreases from sub-micrometers to nanometers” (Wang J. et al.
- MSCs are characterized by their ability to produce daughter stem cells, and to differentiate into many distinct cell types including, but not limited to, osteoblasts, stromal cells that support hematopoiesis and osteoclastogenesis, chondrocytes, myocytes, adipocytes of the bone marrow, neuronal cells, and ⁇ -pancreatic islet cells. Consequently, MSCs provide osteoblasts and stromal cells needed for bone development, bone remodeling and hematopoiesis throughout life.
- Progenitor stem cells of mesenchymal origin migrate to predetermined sites, where they either: (a) condense, proliferate, and differentiate into bone-forming cells (osteoblasts), a process observed in the skull and referred to as “intramembranous bone formation;” or, (b) condense, proliferate and differentiate into cartilage-forming cells (chondroblasts) as intermediates, which are subsequently replaced with bone-forming cells. More specifically, mesenchymal stem cells differentiate into chondrocytes. The chondrocytes then become calcified, undergo hypertrophy and are replaced by newly formed bone made by differentiated osteoblasts, which now are present at the site.
- the mineralized bone is extensively remodeled, thereafter becoming occupied by an ossicle filled with functional bone-marrow elements.
- This process is observed in long bones and referred to as “endochondral bone formation.”
- bone In postfetal life, bone has the capacity to repair itself upon injury by mimicking the cellular process of embryonic endochondral bone development. That is, mesenchymal progenitor stem cells from the bone-marrow, periosteum, and muscle can be induced to migrate to the defect site and begin the cascade of events described above. There, they accumulate, proliferate, and differentiate into cartilage, which is subsequently replaced with newly formed bone.
- MSCs are extremely rare in the bone marrow, and earlier attempts to expand them ex vivo from rodent or human marrow have proven difficult.
- inducing proliferation and differentiation of progenitor cells into functional bone, cartilage, tendon, and/or ligamentous tissue has been shown to require various proteins, including, but not limited to, members of the family of bone morphogenetic proteins (BMPs) and members of the TGF- ⁇ superfamily of growth factors.
- BMPs bone morphogenetic proteins
- TGF- ⁇ superfamily of growth factors members of the family of bone morphogenetic proteins
- Manufacture, isolation, and purification of such proteins is necessarily more complex and expensive than that of small-molecule chemical compounds because proteins are larger, more complex, and are synthesized by a living cell.
- the present disclosure provides, in one embodiment, an isolated cell in a culture medium, said culture medium comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- the isolated cell is a mammalian cell.
- the isolated cell is a stem cell.
- the stem cell is a mesenchymal stem cell.
- the theobromine, salt or double salt of theobromine, or co-crystal comprising theobromine is present in an amount from 1 to 300 ⁇ M.
- the present disclosure provides, in another embodiment, a method of culturing a cell, the method comprising: a) culturing said cell in a culture medium, wherein said culture medium comprises theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- the cell is a mammalian cell.
- the cell is a stem cell.
- the stem cell is a mesenchymal stem cell.
- theobromine is from 1 to 300 ⁇ M.
- the present disclosure provides, in another embodiment, a culture medium comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- the theobromine, salt or double salt of theobromine, or co-crystal comprising theobromine is present in an amount from 1 to 300 ⁇ M.
- the theobromine, salt or double salt of theobromine, or co-crystal comprising theobromine is from 1 to 100 ⁇ M.
- the present disclosure provides, in another embodiment, use of a composition comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, increasing fetal birth weight, or combinations thereof, in a subject in need thereof.
- the present disclosure provides, in another embodiment, use of a composition comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine for preventing tooth decay, remineralizing a tooth surface, treating dentine hypersensitivity, or combinations thereof, in a subject in need thereof.
- the present disclosure provides, in another embodiment, a method for improving maternal and/or child health during the stages of preconception, pregnancy, lactation, and/or postpartum comprising: administering a composition a) to a mother during pregnancy and/or lactation; or b) to a child during the stage of postpartum; wherein the composition comprises theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- the composition benefits at least one of the mother and child, wherein said benefit is selected from the group consisting of increased fetal weight gain, enhanced bone formation, increased bone density, increased interconnections of internal bone, increased bone mass, and combinations thereof.
- the present disclosure provides, in another embodiment, a composition
- a composition comprising: a) demineralized osteogenic bone powder with a particle size of about 250 ⁇ m to about 5 mm; and b) theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- the present disclosure provides use of a composition
- a composition comprising: a) demineralized osteogenic bone powder with a particle size of about 250 ⁇ m to about 5 mm; and b) theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- the present disclosure provides use of a composition comprising a bone cement and theobromine.
- the bone cement may be formed by combining calcium and phosphate precursors in an aqueous solution, which initially forms a paste but then hardens into a hydroxyapatite bone cement when used.
- the bone cement may be a composition comprising at least one calcium phosphate, at least one sodium phosphate, and theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- FIGS. 1A-1C show dose-dependent upregulation of early osteogenic markers by theobromine.
- Human MSCs from two different donors 7011 & 7022 were subjected to 8 days of culture in the presence of osteogenic supplements and the indicated doses of theobromine (1 to 300 ⁇ M). After 8 days, monolayers were assayed for ALP activity ( FIG. 1A ; arbitrary rate units/cell), OPG secretion ( FIG. 1B ; ⁇ g/cell/48 h), and cell number ( FIG. 1C ; cells recovered/cm 2 ).
- FIGS. 2A & 2B show increased ALP activity upon treatment with 10-100 ⁇ M Thb for 8 days.
- Human MSCs from three different donors (281, 7023 & 7057) were subjected to 8 days of culture in the presence of osteogenic supplements and the indicated doses of theobromine (1 to 100 ⁇ M). After 8 days, monolayers were assayed for ALP activity ( FIG. 2A ; arbitrary rate units/cell) and cell number ( FIG. 2B ; cells recovered/cm 2 ).
- FIG. 3 shows tissue clustering for hMSC donor 281 (p-value ⁇ 0.001); entries 1-31 of 31 total.
- FIG. 4 shows tissue clustering for hMSC donor 7023 (p-value ⁇ 0.001); entries 1-31 of 104 total.
- FIG. 5 shows tissue clustering for hMSC donor 7057 (p-value ⁇ 0.001); entries 1-31 of 175 total.
- FIG. 6 shows pathway clustering for donors 281, 7023, and 7057; note that focal adhesion and ECM interactions are present for 2 of the 3 donors.
- FIG. 7 shows the extracellular matrix (ECM) pathway demonstrating upregulation of collagen and alpha V integrin in Thb-treated MSCs (stars indicate genes upregulated in this data set: CD47 molecule; collagen, type XI, alpha 1; integrin, alpha V [vitronectin receptor, alpha polypeptide, antigen CD51]; and laminin, alpha 4).
- ECM extracellular matrix
- FIG. 8 shows the focal adhesion pathway demonstrating upregulation of PI3 kinase through collagen/integrin interactions
- RAP1A member of RAS oncogene family
- actinin alpha 4
- collagen type XI, alpha 1
- epidermal growth factor receptor [erythroblastic leukemia viral [v-erb-b] oncogene homolog, avian]
- filamin B beta [actin binding protein 278]
- glucocorticoid receptor DNA binding factor 1 glycogen synthase kinase 3 beta
- integrin alpha V [vitronectin receptor, alpha polypeptide, antigen CD51]
- laminin alpha 4
- mitogen-activated protein kinase 1 phosphatase and tensin homolog, phosphatase and tensin homolog pseudogene 1
- phosphoinositide-3-kinase regulatory subunit 1 [alpha]
- son mitogen-activated protein kina
- FIGS. 9A-9H show measurements obtained from rats of EXAMPLE 3, described below.
- FIG. 10 shows a rat femur from EXAMPLE 3 being subjected to testing as described for, for example, FIGS. 9A-9H .
- the expression of genes implicated in osteogenesis is significantly increased in MSCs after incubation with theobromine.
- theobromine is involved in promoting fetal weight gain, enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, or combinations thereof, in a subject in need thereof, and improving maternal and/or child health during the stages of preconception, pregnancy, lactation, and/or postpartum. Without wishing to be bound by theory, Applicant believes these results may occur through the actions of theobromine on MSCs.
- One embodiment of the present disclosure provides for overall improvement of pregnancy outcomes and/or birth weight related to theobromine supplementation, resulting in increased fetal weight gain, enhanced bone formation, increased bone density, increased interconnections of internal bone, increased bone mass, and combinations thereof.
- maternal nutritional formulations comprising theobromine are provided for preconception, pregnancy, and lactation/postpartum.
- the maternal route of supplementation represents an opportunity to supply theobromine to the developing infant in an effective and efficient manner in addition to or instead of infant formula formulated with theobromine.
- infant nutritional formulations comprising theobromine are provided.
- Preconception is defined as the period during which a women is attempting to become pregnant. This is important because preparing for pregnancy is just as important as being pregnant and many women who are trying to become pregnant are pregnant for a month or more before they realize it. Lactation/postpartum is from delivery until two years later, or until breast-feeding is stopped. It will be understood that supplementation can have benefits for the mother even if the mother is not breast-feeding the child. It will be understood that supplementation is preferred, but not required, during each stage, and is preferred, but not required, continuously throughout each stage.
- any human in need thereof e.g., man, woman, child of either gender
- any human in need thereof in need of enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, or combinations thereof, may benefit from the supplements described herein.
- a person in need thereof could be one at risk of developing or diagnosed with osteoporosis.
- Osteoporosis is a disease of bone that leads to an increased risk of fracture. In a person suffering from osteoporosis, bone mineral density is reduced, bone microarchitecture is disrupted, and the amount and variety of non-collagenous proteins in bone is altered.
- the World Health Organization (WHO) defines osteoporosis (in women) as a bone mineral density 2.5 standard deviations below peak bone mass (versus an average 30-year-old healthy female).
- Osteoporosis is most common in women after menopause, where it is called postmenopausal osteoporosis, but may also develop in men, and may occur in anyone in the presence of particular hormonal disorders and other chronic diseases or as a result of medications (e.g., glucocorticoids) where the disease is called steroid- or glucocorticoid-induced osteoporosis, and as a result of nutritional deficiency states or other metabolic disorders, including, but not limited to, hyponatremia or as a secondary consequence of cancer. Given its influence on the risk of fragility fracture, osteoporosis may significantly affect life expectancy and quality of life. About 20 percent of senior citizens who suffer a hip fracture die within a year of fracture.
- medications e.g., glucocorticoids
- One embodiment of the present disclosure provides compositions and methods for treating osteoporosis, said compositions comprising theobromine.
- any biologically acceptable dosage forms, and combinations thereof, are contemplated by the inventive subject matter.
- dosage forms include, without limitation, chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi-layer tablets, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, beads, powders, granules, particles, microparticles, dispersible granules, cachets, douches, suppositories, creams, topicals, inhalants, aerosol inhalants, patches, particle inhalants, implants, depot implants, ingestibles, injectables, infusions, health bars, confections, cereals, cereal coatings, foods, nutritive foods, functional foods, dental varnish, and combinations thereof.
- a theobromine varnish (a concentrated form of theobromine for application to the surface, the enamel, the dentine, and or cementum of at least one tooth) may provide topical theobromine therapy to a person in need thereof to, for example and without limitation, help prevent decay, remineralize the tooth surface, and treat dentine hypersensitivity.
- the preparations of the above dosage forms are well known to persons of ordinary skill in the art.
- foods enriched with theobromine are selected from the group including:
- baked goods and mixes e.g., bread); chewing gum; breakfast cereals; cheese products; nuts and nut products; gelatins, pudding, custard, and fillings; frozen dairy products; milk products (e.g., meal-replacement beverages, yogurt, yogurt drinks); dairy product analogs; hard candy; soft candy; soups and soup mixes; snack foods; beverages; processed fruit juice; fruit smoothies; powdered fruit-flavored drinks; processed vegetable juice; sports or isotonic drinks; meal-replacement beverages; non-milk-based beverages (e.g., soy milk); bottled water (e.g., vitamin, enhanced, and bottled waters); coffee; tea; fats and oils; fish products; plant protein products; poultry products; and meat products;
- milk products e.g., meal-replacement beverages, yogurt, yogurt drinks
- dairy product analogs hard candy; soft candy; soups and soup mixes
- snack foods beverages
- processed fruit juice; fruit smoothies powdered fruit-flavored drinks
- processed vegetable juice sports or isotonic drinks
- baked goods and mixes more preferably, baked goods and mixes; breakfast cereals; gelatins, puddings, and fillings; dairy product analogs; soups and soup mixes; poultry products; nuts and nut products; frozen dairy;
- nuts and nut products are preferably, nuts and nut products; frozen dairy; milk products; soft candy; plant protein products; fats and oils; and
- the supplement is preferably administered during one or more of the three stages of pregnancy: preconception, pregnancy, and during lactation/postpartum.
- the supplement is administered during preconception, pregnancy, and during lactation/postpartum.
- the maternal supplement is administered during preconception and during pregnancy and during lactation/postpartum.
- the maternal supplement is administered during lactation/postpartum.
- a surgical bone defect filling product comprising theobromine. More specifically, the surgical bone defect filling product comprises theobromine and allograft bone.
- the surgical bone defect filling product may further comprise gelatin, with the gelatin being cross linked by lyophilization of the composition to form a solid composition which is later rehydrated for application to a bone defect area.
- the surgical bone defect filling product may be a shaped osteoimplant, meaning a predetermined or regular form or configuration in contrast to an indeterminate or vague form or configuration and by way of example would be characteristic to a wedge, cylinder, disk, plate sheet, tube and the like.
- the surgical bone defect filling product may comprise partially demineralized bone material (e.g., having a residual calcium content ranging between about 3 to about 10%, preferably 4 to 6%).
- partially demineralized bone material e.g., having a residual calcium content ranging between about 3 to about 10%, preferably 4 to 6%.
- a sterile malleable bone composition for application to a bone defect site to promote new bone growth at the site comprising theobromine and demineralized osteogenic bone powder with a particle size ranging from about 250 to about 750 microns.
- the composition comprises theobromine and demineralized osteogenic bone particles with a particle size ranging from about 0.1 to about 5 mm, from about 0.1 to about 4 mm, from about 0.1 to about 3 mm, from about 0.1 to about 2 mm, and from about 0.1 to about 1 mm.
- Fetal calvaria cells were cultured in 24-well culture plates using D-MEM and supplemented with 10% (V/V) FBS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. The cells were cultured in medium with various concentrations (0.1, 1.0, 10, 20, 40, 60, and 100 ⁇ M) of theobromine and without theobromine (control) for 96 hours, then counted using trypan blue dye exclusion method after culture. The results are shown below in TABLE 3.
- UMR 106-01 rat obsteoblast-like cells were cultured in 24-well culture plates using D-MEM supplemented with 10% (V/V) FBS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin.
- the cells were cultured in medium with various concentrations (0.0027. 0.027, 0.27, 2.7, 27, and 270 ⁇ M) of theobromine and without theobromine (control) for 96 hours, then counted using trypan blue dye exclusion method. The results are shown in TABLE 4.
- Statistical analysis was done using Student's t-test. P-values less than 5% were considered statistically significant.
- Thb theobromine
- the Thb dose was approximately 1 mg per 100 g body mass in food.
- the average weight during pregnancy and the average food intake was approximated. Approximations were based on the study sponsor's prior experience, data from Harlan laboratories, and data from Keenan et al. “The Effects of Overfeeding and Dietary Restriction on Sprague-Dawley Rat Survival and Early Pathology Biomarkers of Aging” Toxicol Pathol. 1994; 22:300.
- the test diet consisted of 113 mg of finely ground Thb powder mixed well with 1 kg of powdered chow. birth was predicted to occur during the afternoon of day 22 or early morning of day 23. Postnatal theobromine doses were as follows: 88 mg/kg for postnatal days 1 to 14; 59 mg/kg for postnatal days 14 to 22. After weaning, theobromine was added to the diet of offspring as follows: 89 mg/kg for postnatal days 22 to 29; 42 mg/kg for postnatal days 29 to 50. These concentrations in the diet were calculated to provide about 1 mg/100 gram of body weight of theobromine per day, based on total food intake. Only female pups were used for data acquisition. Male pups were either humanely euthanized by lethal injection or transferred to another protocol. In some instances, males were used to normalize suckling litter sizes.
- Postnatal Sixteen female pups per group were required for analysis, but up to 40 were utilized due to leveling of litter sizes. To minimize maternally-introduced variance during nursing, equal numbers of female neonates derived from each litter were randomized and re-allocated to each of the mothers. The appropriate diet (Thb or control) was continuously fed to the postnatal mothers. Thus, postnatal mothers fed Thb provided Thb via milk to nursing pups during the nursing interval. Pups were marked via tail tattoo or ear punch to maintain identity with offspring and dam.
- Euthanasia fifty days after birth, half of the pups in each group were humanely euthanized by intraperitoneal injection of pentobarbital (100 mg/kg), CO 2 inhalation, or inhalation overdose of isoflurane. These methods are acceptable under the guidelines of the American Veterinary Medical Association. Shortly after death was confirmed, left hindlimbs with intact femoral head were dissected from the pelvis and placed in phosphate buffered formalin for biomechanical testing. Right femurs were cut at the condyles with rongeurs, and the marrow flushed into alpha minimal essential medium ( ⁇ -MEM) containing penicillin, streptomycin and amphotericin B with 2% bovine serum. Marrow cells, preserved on wet ice in sterile media, were shipped via courier to the Institute for Regenerative Medicine for analysis.
- ⁇ -MEM alpha minimal essential medium
- Thb Theobromine (Thb): Thb was prepared as 100 ⁇ -1000 ⁇ aliquots on water by warming at 60° C. for 15 min prior to centrifugation at 2500 g for 15 min. Because the solubility of Thb in water is frequently incomplete and unstable at the concentrations required for generation of stock solutions, spectrophotometry at 260 nm was used to confirm concentration of stocks. With warming, it was possible solubilize about 500 mg in 50 mL of water, which is close to the published solubility in the Merck index. It was noted that storage at 4° C. caused solubility to drop substantially, necessitating re-solubilization at each media replenishment.
- hMSC differentiation assays a carrier comprised of 10 mM NH 4 OH.
- a carrier comprised of 10 mM NH 4 OH.
- cells were tested with 1-500 ⁇ mol/mL (0.18-90 ⁇ g/mL).
- the volume of carrier (NH 4 OH) necessary to attain these concentrations did not affect the pH of the culture, but substantially inhibited osteogenic differentiation.
- solubility of Thb in water is about half that of an alkaline carrier, water was used water as a carrier because the amount of water that can be added to hMSC cultures is much higher.
- Thb Water solutions of Thb are unstable until diluted to a working concentration.
- the extinction coefficient of Thb in H 2 O was calculated at 260 nm and stock solutions screened after warming to confirm the amounts added to the cells. With this protocol, a maximum of 100 ⁇ g/mL was added to media.
- Plastic adherent, nucleated cells were separated from the aspirate by culturing in ⁇ -MEM (Gibco, Invitrogen, Carlsbad, Calif.) containing 20% (v/v) fetal calf serum (FCS; Atlanta Biochemical, Norcross, Ga.), 100 ⁇ g/mL streptomycin, 100 U/mL penicillin, and 2 mM glutamine (Gibco, Invitrogen). After 14 days in culture, adherent cells were recovered from the monolayer by incubation with 0.25% (w/v) trypsin and 1 mM EDTA (Fisher Lifesciences; Pittsburgh, Pa.) for 5 to 7 min at 37° C.
- ALP Alkaline Phosphatase
- OPG Osteoprotegerin
- pNPP para-nitrophenylphosphate
- ALP buffer 1.5 mL of a 1:2 solution of para-nitrophenylphosphate (pNPP; Fisher) and ALP buffer was added to the wells to produce a 5 mm path length between the bottom of the well and the meniscus.
- ALP activity as a function of pNPP metabolism was measured using a temperature-controlled automated plate reader (FluoStar, BMG Biotech, Chicago, Ill.). The rates were compared against standards with a known concentration of ALP and normalized against cell number.
- OPG ELISAs antibody set from R and D Systems
- Cells were recovered by trypsinization, then the number of cells per well was measured by nucleic acid fluorescence incorporation assay. The cells were added to 2 ⁇ CyQuant dye solution (Molecular Probes Incorporated; Eugene, Oreg.). Nucleic acid intercalation-induced fluorescence was measured using a microplate fluorescence reader (FLX800; Bio-Tek Instruments Incorporated; Winooski, Vt.) set to 480 nm excitation and 520 nm emission. The degree of fluorescence was directly proportional to cell number when compared against known standards.
- RNA from 1 ⁇ 10 6 cells was isolated using an RNA isolation kit (High Pure, Roche, Nutley, N.J.) and used to synthesize double-stranded cDNA (Superscript Choice System; Invitrogen).
- Biotin-labelled cRNA GeneChip In Vitro Trancription labeling Kit; Affymetrix, Santa Clara, Calif.
- RNAeasy Mini Kit Qiagen, Valencia, Calif.
- fragmented and hybridized on HG-U133 Plus 2.0 microarray chips (Affymetrix).
- microarray chips were stained with streptavidin-phycoerythrin (Invitrogen), amplified with biotinylated anti-streptavidin (Vector Laboratories, Burlingame, Calif.), stained with streptavidin-phycoerythrin, then scanned (GeneChip Scanner 3000, Affymetrix) using GeneChip Operating software 1.0 (GCOS, Affymetrix). Data were analyzed using dChip software. Expression levels (as functions of arbitrary densitometric values from the array scans) were used to generate lists of upregulated genes (at least 2-fold).
- the database assigns a p-value which represents the probability that the experimental gene list (e.g., hMSCs treated with Thb) has a given proportion of tissue specific genes due entirely to chance.
- p-values become quite small because the process involves hundreds or even thousands of transcripts.
- Preliminary Biochemical Assays on hMSCs To define dosage and duration of treatment, confluent cultures of hMSCs (2 donors) were exposed to osteogenic supplements in the presence of various doses of Thb. After 5-10 days, a measurement of ALP activity or OPG secretion was carried out on the monolayers. The early osteogenic markers were upregulated by Thb in a dose dependent, biphasic manner that reached maximum effect at 100 ⁇ M Thb ( FIGS. 1A & 1B ). The magnitude of the increase was detectable after 4 days, but was most prominent after 8 days of exposure (data not shown). Slight cell loss was also evident at high doses, but was marginal in most cases ( FIG. 1C ).
- the first set of analyses were designed to address the hypothesis “Is there a statistically significant upregulation of genes commonly related to osteogenesis in hMSCs exposed to Thb?”
- the upregulated gene lists were compared to tissue expression databases using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 database handler maintained by the National Institute of Allergy and Infectious Diseases (NIAID), NIH (available at david.abcc.ncifcrf.gov).
- DAVID Database for Annotation, Visualization and Integrated Discovery
- NIH available at david.abcc.ncifcrf.gov.
- “bone gene” enrichment is in the top 3.5% of statistically significant tissue expression signatures ( FIG. 3 , donor 281; and FIG. 4 , donor 7023), and this represented the first or second on the list.
- the bone signature was in the top 9% of the list, but the overall list was longer.
- the variation in the size of the lists for each hMSC preparation indicates that the different cell lines exhibit different degrees of plasticity and in maximally multipotential cells, the effects of Thb seem to be pleiotropic (e.g., in 7057), whereas in hMSCs with less pluripotency bone is by far the preferred path (e.g., donors 281 and 7023). This is quite normal, since hMSCs from different donors exhibit donor-dependent variability depending on donor age, sex, degree of expansion, culture conditions etc. Nevertheless, even in profoundly pluripotent hMSC lines, bone is high on the list.
- Thb upregulated genes were then used to probe the signal transduction pathway database to test whether Thb had a preferential molecular mode of action. There were few hits, suggesting that Thb may transduce its action through a novel pathway. Nevertheless, extracellular matrix and focal adhesion signaling pathways were significantly represented in donors 281 and 7023 (those with a highly significant osteoblast signature). ECM interations and focal adhesion signaling are generally mediated through collagen-integrin mediated pathways via PI3 kinase (see FIGS. 7 & 8 ). It is therefore possible that Thb causes a feed-forward loop through upregulation of collagen, integrin and PI3 kinase signaling.
- an Instron Universal Testing Instrument was employed to test the femurs of EXAMPLE 3 for strength and flexibility.
- a special metal holding device for the femurs was used so that the diaphysis was loaded anteriorly at the midpoint The force, F, was applied midway between these supports on the anterior surface.
- the load at the elastic limit, maximum load, and load at the breaking point were measured on the x-axis, and the amounts of deflection at these loads were measured on the y axis.
- the length of the portion of each specimen that was used to make the measurement is the same, 15 mm, for all.
- Data from femurs of theobromine-treated rats are provided in TABLES 5.1 and 5.2, while the study parameters are provided in TABLES 5.3 and 5.4.
- Data from femurs of control rats are provided in TABLES 6.1 and 6.2, while the study parameters are provided in TABLES 6.3 and 6.4.
- sample width and thickness were significantly greater in the theobromine group compared to controls.
- Femur length was also significantly greater in the theobromine group, compared to controls.
- Modulus (stiffness/rigidity) the theobromine group (3161.36) was not significantly different from that of the control group (3536.858). This result may be due to the mean cross-section of the treated group being numerically greater than that of the control group (cross-section is shown by width and thickness measurements). Consequently, a numerically greater amount of energy was required to break the bones of the treated group compared to those of the control group: Energy to break in the treated was 28.516, whereas the control was 25.238. Strength and modulus factor were measured in the cross-sectional area, so they are normalized values.
- FIG. 9A shows the weight (grams) of rat pups in the study of EXAMPLE 3 at the days indicated.
- the three right-most columns indicate the weight over time of theobromine-treated rats, while the three left-most columns indicate the weight over time of the control rats.
- FIG. 9B shows the weight (grams) of the rat pups in the study of EXAMPLE 3 at day 40.
- body weight of theobromine group was significantly greater than that of the control group.
- the mean weight of the theobromine group was about 171 g, whereas for the control group it was about 160 g.
- Bone data of FIGS. 9C, 9D, 9E, 9F, 9G, and 9H were obtained by utilizing high resolution micro-computer aided tomography to evaluate bone quality.
- FIG. 9C shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating the number of trabeculae of control and theobromine-treated rats. These data reflect the formation of bone, and demonstrate significantly more bone formation in theobromine-treated rats, versus controls.
- FIG. 9D shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating trabecular bone spacing. Significantly less spacing between the trabecular bone was observed in the theobromine-treated group compared to the control group, suggesting greater trabecular bone formation in the theobromine-treated rats. This is a very important aspect of bone formation by feeding theobromine.
- FIG. 9E shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating trabecular bone thickness. No significant difference was observed between the theobromine-treated group and the control group, but these data do not indicate whether density within the hard tissue is different or not.
- FIG. 9F shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating the percent volume of trabecular bone. Although the difference between the theobromine-treated group and the control group is not statistically significant, the theobromine-treated group was slightly elevated over the control group.
- FIG. 9G shows data obtained from femurs of rat pups from EXAMPLE 3, demonstrating bone area at the midshaft of each femur.
- the trabecular bone area of femurs from the theobromine-treated group was significantly greater (indicating thicker bone) than that of the control group.
- FIG. 9H shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating trabecular bone area.
- the trabecular bone area of proximal tibia of theobromine-treated rats was significantly greater (indicating thicker bone) than that of the control group.
- FIGS. 9A, 9B, 9C, 9D, 9E, 9F, 9G, and 9H demonstrate that ingestion of theobromine during growth enhances body weight over time ( FIGS. 9A & 9B ), enhances bone formation overall ( FIG. 9C ), especially trabecular bone formation ( FIG. 9D ), and enhances bone area ( FIGS. 9G & 9H ).
Abstract
Description
- This application is a divisional of U.S. patent application Ser. No. 14/775,104, filed 11 Sep. 2015, which is a National Stage entry of International Application No. PCT/US2014/027018, filed 14 Mar. 2014, which claims priority to U.S. Provisional Application No. 61/792,425, filed 15 Mar. 2013. The disclosures of the priority applications are incorporated in their entirety herein by reference.
- The present disclosure relates to compositions and methods for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, or combinations thereof, in a subject in need thereof, improving maternal and/or child health during the stages of preconception, pregnancy, lactation, and/or postpartum, and increasing osteoblastic/osteogenic activity in mesenchymal stem cells (MSCs; also called “marrow stromal cells” or “multipotent stromal cells”). More particularly, said compositions comprise cocoa extract.
- Theobromine (IUPAC name: 3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; also known as 3,7-dimethylxanthine) is a white (or colorless) bitter-tasting crystalline powder with a sublimation point of 290-295° C., a melting point of 357° C., and a molecular weight of 180.16 g/mol. The solubility of theobromine in water is 1.0 g/2 L; in boiling water, it is 1.0 g/150 mL, and in 95% ethanol it is 1.0 g/2.2 L. Theobromine is related chemically to caffeine and theophylline, and is found in numerous foods including chocolate, cocoa, tea leaves, and acai berries. The chemical structures of theobromine, theophylline (1,3-dimethylxanthine), and caffeine (1,3,7-trimethylxanthine) are given below as formulae I, II, and III, respectively.
- Theobromine is found naturally in cacao beans (Theobroma cacao) at a concentration of from about 1.5% to about 3%, and in the husk of the bean at a concentration of from about 0.7% to about 1.2%, or about 15 to about 30 g/Kg (Winholdz, 1983). Though part of the same chemical family, one must distinguish the stimulant effects of theobromine from those of caffeine. Caffeine acts relatively quickly, and its main effect on humans is increased mental alertness; theobromine's effect is subtler, and causes a mood elevation that is milder longer-lasting than that of caffeine. Theobromine's plasma half-life (t1/2) in the bloodstream is six hours, while caffeine's is only two hours. Another difference is that theobromine is not physiologically addictive, producing no withdrawal symptoms after prolonged regular consumption, while caffeine has been proven to be physiologically addictive and linked with many cases of proven withdrawal.
- As used herein, “theobromine” refers to theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- Two independent studies conducted in the 1980's found that the average level of theobromine in eight varieties of commercial cocoa powder was 1.89% (Shively & Tarka, 1984 and Zoumas et al., 1980). Of particular relevance are the normal levels of theobromine found in commercially-available foodstuffs, shown below in TABLE 1.
-
TABLE 1 Food Type Theobromine Content hot chocolate beverages 65 mg/5-oz serving chocolate milk (from instant or 58 mg/serving sweetened cocoa powder) hot cocoa (average of 9 commercial mixes) 62 mg/serving cocoa cereals* 0.695 mg/g chocolate bakery products* 1.47 mg/g chocolate toppings* 1.95 mg/g cocoa beverages* 2.66 mg/g chocolate ice cream* 0.621 mg/g chocolate milk* 0.226 mg/g chocolate pudding* 74.8 mg/serving carob products* 0-0.504 mg/g Sources: Zoumas, et al., 1980; Blauch & Tarka, 1983; Shivley & Tarka, 1984; Craig & Nguyen, 1984. *Theobromine content determined by HPLC/reverse-phase column chromatography - Dark chocolate contains the highest levels of theobromine per serving of any type of chocolate, but the concentrations tends to vary between about 0.36% and about 0.63%. To put this into perspective with the foodstuffs mentioned in TABLE 1, a one-ounce bar of dark chocolate contains about 130 mg of theobromine, while a one ounce bar of milk chocolate contains about 44 mg of theobromine. Thus, the concentration of theobromine in a one-ounce bar of dark chocolate is approximately two times the amount in a 5-ounce cup of hot chocolate. For a 143-pound human being to achieve a toxic level of theobromine in their blood, they would have to ingest approximately 86 one-ounce milk chocolate bars in one sitting.
- Theobromine can also be isolated or produced as an amine salt (e.g., the ethylene diamine salt thereof) or a double salt thereof (e.g., with alkali metal salts or alkaline earth metal salts of organic acids, for example alkali or alkaline earth metal salts of acetic, gluconic, benzoic, or salicylic acid). The double salts may be prepared either to make the theobromine more water souble, or to make insoluble complexes.
- In 1966, Strålfors reported a reduction of dental caries in hamsters that were fed diets rich in chocolate. The Strålfors study examined the effect on hamster caries by comparing cocoa powder, defatted cocoa powder, and cocoa fat. Pure cocoa powder inhibited dental caries by 84%, 75%, 60%, and 42% when the cocoa powder comprised 20%, 10%, 5%, and 2% percent of the hamster diet, respectively. Defatted cocoa showed a significantly higher anti-caries effect than did fat-containing cocoa powder, but cocoa butter alone (comprising 15% of the hamster's diet) increased dental caries significantly (Strålfors A. “Effect on Hamster Caries by Dialyzed, Detanned or Carbon-treated Water-Extract of Cocoa” Arch OralBiol. 1966; 11:609-15.
- In a follow up study, Strålfors studied the nonfat portions of the cocoa powder and demonstrated that cocoa powder washed with water possessed considerably less anti-cariogenic effect than unwashed cocoa powder. Nevertheless, Strålfors still observed a considerable anti-caries effect in the washed cocoa powder group, “indicating an existence of a non-water soluble cariostatic factor,” and alluded to the existence of “two caries-inhibitory substances in cocoa: one water-soluble, and another which is sparingly soluble in water” (Strålfors, A., 1966).
- Subsequent studies suggested that apatite crystals grown in vitro in the presence of theobromine were significantly larger than those grown in the absence of theobromine (see, e.g., U.S. Pat. Nos. 5,919,426 and 6,183,711, each of which is incorporated by reference in its entirety). Ingestion of theobromine by lactating rats was correlated with increased hydroxylapatite crystallite size (higher crystallinity) in the whole first molars of nursing pups exposed to theobromine, versus controls, as well as increased resistance to acid dissolution (see id.). The femurs of nursing female pups exposed to theobromine demonstrated higher crystallinity, and were stronger and stiffer than gender-matched controls; the femurs of male pups, however, did not show this relationship (see id.).
- The Hall-Petch relationship, however, dictates that the resistance of a solid material to permanent deformation (e.g., its indentation hardness) increases as the particle size decreases. Consequently, the increased hydroxylapatite crystallinity observed after exposure to theobromine—coupled with the Hall-Petch relationship—suggests that the resistance of bone and teeth to indentation and permanent deformation should decrease after exposure to theobromine due to the larger crystal size. This suggestion finds support in recent work, demonstrating that “the hardness of [hydroxylapatite] follows the Hall-Petch relationship as the grain size decreases from sub-micrometers to nanometers” (Wang J. et al. “Nanocrystalline hydroxyapatite with simultaneous enhancements in hardness and toughness” Biomaterials. 2009; 30:6565-72). Another study suggests that the “hardness” of hydroxylapatite has little to do with particle size, showing almost no change in hardness with decreasing grain size, yet demonstrates that the “fracture toughness” of hydroxylapatite is increased with decreasing particle size (Mazaheri M, et al. “Effect of a novel sintering process on mechanical properties of hydroxyapatite ceramics.” J. Alloys Compd. 2009; 471:180-4). A study of human adult and primary (baby) teeth demonstrated that, “[w]hen compared to the adult tooth, the baby enamel was thinner, softer, more prone to fracture, and possessed larger [hydroxylapatite] grains” (Low I M, et al. “Mapping the structure, composition and mechanical properties of human teeth.” Mater Sci Eng C Mater Biol App. 2008; 28:243-47.).
- Because of such conflicting and paradoxical results, one cannot extrapolate the known characteristics and responses of hydroxylapatite to environmental factors to predict a reliable or accurate result cannot be predicted simply by evaluating the prior art and extrapolating a result.
- MSCs are characterized by their ability to produce daughter stem cells, and to differentiate into many distinct cell types including, but not limited to, osteoblasts, stromal cells that support hematopoiesis and osteoclastogenesis, chondrocytes, myocytes, adipocytes of the bone marrow, neuronal cells, and β-pancreatic islet cells. Consequently, MSCs provide osteoblasts and stromal cells needed for bone development, bone remodeling and hematopoiesis throughout life.
- In humans, bone formation begins during the first 6-8 weeks of fetal development. Progenitor stem cells of mesenchymal origin migrate to predetermined sites, where they either: (a) condense, proliferate, and differentiate into bone-forming cells (osteoblasts), a process observed in the skull and referred to as “intramembranous bone formation;” or, (b) condense, proliferate and differentiate into cartilage-forming cells (chondroblasts) as intermediates, which are subsequently replaced with bone-forming cells. More specifically, mesenchymal stem cells differentiate into chondrocytes. The chondrocytes then become calcified, undergo hypertrophy and are replaced by newly formed bone made by differentiated osteoblasts, which now are present at the site. Subsequently, the mineralized bone is extensively remodeled, thereafter becoming occupied by an ossicle filled with functional bone-marrow elements. This process is observed in long bones and referred to as “endochondral bone formation.” In postfetal life, bone has the capacity to repair itself upon injury by mimicking the cellular process of embryonic endochondral bone development. That is, mesenchymal progenitor stem cells from the bone-marrow, periosteum, and muscle can be induced to migrate to the defect site and begin the cascade of events described above. There, they accumulate, proliferate, and differentiate into cartilage, which is subsequently replaced with newly formed bone.
- MSCs are extremely rare in the bone marrow, and earlier attempts to expand them ex vivo from rodent or human marrow have proven difficult. Moreover, inducing proliferation and differentiation of progenitor cells into functional bone, cartilage, tendon, and/or ligamentous tissue has been shown to require various proteins, including, but not limited to, members of the family of bone morphogenetic proteins (BMPs) and members of the TGF-β superfamily of growth factors. Manufacture, isolation, and purification of such proteins is necessarily more complex and expensive than that of small-molecule chemical compounds because proteins are larger, more complex, and are synthesized by a living cell.
- Thus, there remains a need for small-molecule chemical compounds—especially ones known to be non-toxic—capable of inducing proliferation of progenitor cells into functional bone, cartilage, tendon, and/or ligamentous tissue.
- The solution to this technical problem is provided by the embodiments characterized in the claims.
- The present disclosure provides, in one embodiment, an isolated cell in a culture medium, said culture medium comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine. In a further embodiment, the isolated cell is a mammalian cell. In a further embodiment, the isolated cell is a stem cell. In a further embodiment, the stem cell is a mesenchymal stem cell. In a further embodiment, the theobromine, salt or double salt of theobromine, or co-crystal comprising theobromine is present in an amount from 1 to 300 μM.
- The present disclosure provides, in another embodiment, a method of culturing a cell, the method comprising: a) culturing said cell in a culture medium, wherein said culture medium comprises theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine. In a further embodiment, the cell is a mammalian cell. In a further embodiment, the cell is a stem cell. In a further embodiment, the stem cell is a mesenchymal stem cell. In a further embodiment, the theobromine is from 1 to 300 μM.
- The present disclosure provides, in another embodiment, a culture medium comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine. In a further embodiment, the theobromine, salt or double salt of theobromine, or co-crystal comprising theobromine is present in an amount from 1 to 300 μM. In a further embodiment, the theobromine, salt or double salt of theobromine, or co-crystal comprising theobromine is from 1 to 100 μM.
- The present disclosure provides, in another embodiment, use of a composition comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, increasing fetal birth weight, or combinations thereof, in a subject in need thereof.
- The present disclosure provides, in another embodiment, use of a composition comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine for preventing tooth decay, remineralizing a tooth surface, treating dentine hypersensitivity, or combinations thereof, in a subject in need thereof.
- The present disclosure provides, in another embodiment, a method for improving maternal and/or child health during the stages of preconception, pregnancy, lactation, and/or postpartum comprising: administering a composition a) to a mother during pregnancy and/or lactation; or b) to a child during the stage of postpartum; wherein the composition comprises theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine. In a further embodiment, the composition benefits at least one of the mother and child, wherein said benefit is selected from the group consisting of increased fetal weight gain, enhanced bone formation, increased bone density, increased interconnections of internal bone, increased bone mass, and combinations thereof.
- The present disclosure provides, in another embodiment, a composition comprising: a) demineralized osteogenic bone powder with a particle size of about 250 μm to about 5 mm; and b) theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- In a further embodiment, the present disclosure provides use of a composition comprising: a) demineralized osteogenic bone powder with a particle size of about 250 μm to about 5 mm; and b) theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- In a further embodiment, the present disclosure provides use of a composition comprising a bone cement and theobromine. For example, without intending to be limited, the bone cement may be formed by combining calcium and phosphate precursors in an aqueous solution, which initially forms a paste but then hardens into a hydroxyapatite bone cement when used. The bone cement may be a composition comprising at least one calcium phosphate, at least one sodium phosphate, and theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.
- For a further understanding of the nature, objects, and advantages of the present disclosure, reference should be had to the following detailed description, read in conjunction with the following drawings, wherein like reference numerals denote like elements.
-
FIGS. 1A-1C show dose-dependent upregulation of early osteogenic markers by theobromine. Human MSCs from two different donors (7011 & 7022) were subjected to 8 days of culture in the presence of osteogenic supplements and the indicated doses of theobromine (1 to 300 μM). After 8 days, monolayers were assayed for ALP activity (FIG. 1A ; arbitrary rate units/cell), OPG secretion (FIG. 1B ; μg/cell/48 h), and cell number (FIG. 1C ; cells recovered/cm2). -
FIGS. 2A & 2B show increased ALP activity upon treatment with 10-100 μM Thb for 8 days. Human MSCs from three different donors (281, 7023 & 7057) were subjected to 8 days of culture in the presence of osteogenic supplements and the indicated doses of theobromine (1 to 100 μM). After 8 days, monolayers were assayed for ALP activity (FIG. 2A ; arbitrary rate units/cell) and cell number (FIG. 2B ; cells recovered/cm2). -
FIG. 3 shows tissue clustering for hMSC donor 281 (p-value<0.001); entries 1-31 of 31 total. -
FIG. 4 shows tissue clustering for hMSC donor 7023 (p-value<0.001); entries 1-31 of 104 total. -
FIG. 5 shows tissue clustering for hMSC donor 7057 (p-value<0.001); entries 1-31 of 175 total. -
FIG. 6 shows pathway clustering fordonors -
FIG. 7 shows the extracellular matrix (ECM) pathway demonstrating upregulation of collagen and alpha V integrin in Thb-treated MSCs (stars indicate genes upregulated in this data set: CD47 molecule; collagen, type XI,alpha 1; integrin, alpha V [vitronectin receptor, alpha polypeptide, antigen CD51]; and laminin, alpha 4). -
FIG. 8 shows the focal adhesion pathway demonstrating upregulation of PI3 kinase through collagen/integrin interactions (stars indicate genes upregulated in this data set: RAP1A, member of RAS oncogene family; actinin,alpha 4; collagen, type XI,alpha 1; epidermal growth factor receptor [erythroblastic leukemia viral [v-erb-b] oncogene homolog, avian]; filamin B, beta [actin binding protein 278]; glucocorticoid receptorDNA binding factor 1;glycogen synthase kinase 3 beta; integrin, alpha V [vitronectin receptor, alpha polypeptide, antigen CD51]; laminin,alpha 4; mitogen-activatedprotein kinase 1; phosphatase and tensin homolog, phosphatase andtensin homolog pseudogene 1; phosphoinositide-3-kinase, regulatory subunit 1 [alpha]; and son of sevenless homolog 1). -
FIGS. 9A-9H show measurements obtained from rats of EXAMPLE 3, described below. -
FIG. 10 shows a rat femur from EXAMPLE 3 being subjected to testing as described for, for example,FIGS. 9A-9H . - Before the subject disclosure is further described, it is to be understood that the disclosure is not limited to the particular embodiments of the disclosure described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present disclosure will be established by the appended claims.
- In this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs.
- As shown by the data below, the expression of genes implicated in osteogenesis is significantly increased in MSCs after incubation with theobromine. Also shown below, theobromine is involved in promoting fetal weight gain, enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, or combinations thereof, in a subject in need thereof, and improving maternal and/or child health during the stages of preconception, pregnancy, lactation, and/or postpartum. Without wishing to be bound by theory, Applicant believes these results may occur through the actions of theobromine on MSCs.
- Adults with higher birth weights are less likely to suffer or die from cardiovascular disease and suffer from high blood pressure. Therefore, reduced adult cardiovascular-related death and decreased systolic blood pressure are possible outcomes of adequate theobromine supply during preconception and pregnancy. One embodiment of the present disclosure provides for overall improvement of pregnancy outcomes and/or birth weight related to theobromine supplementation, resulting in increased fetal weight gain, enhanced bone formation, increased bone density, increased interconnections of internal bone, increased bone mass, and combinations thereof.
- In accordance with another embodiment of the present invention, maternal nutritional formulations (including nutritional supplements and foods) comprising theobromine are provided for preconception, pregnancy, and lactation/postpartum. The maternal route of supplementation represents an opportunity to supply theobromine to the developing infant in an effective and efficient manner in addition to or instead of infant formula formulated with theobromine.
- In accordance with another embodiment of the present invention, infant nutritional formulations (including nutritional supplements and foods) comprising theobromine are provided.
- Preconception is defined as the period during which a women is attempting to become pregnant. This is important because preparing for pregnancy is just as important as being pregnant and many women who are trying to become pregnant are pregnant for a month or more before they realize it. Lactation/postpartum is from delivery until two years later, or until breast-feeding is stopped. It will be understood that supplementation can have benefits for the mother even if the mother is not breast-feeding the child. It will be understood that supplementation is preferred, but not required, during each stage, and is preferred, but not required, continuously throughout each stage.
- Nor are the supplements described herein limited to maternal and/or infant use. Any human in need thereof (e.g., man, woman, child of either gender) in need of enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, or combinations thereof, may benefit from the supplements described herein. For example, and without limitation, a person in need thereof could be one at risk of developing or diagnosed with osteoporosis.
- Osteoporosis is a disease of bone that leads to an increased risk of fracture. In a person suffering from osteoporosis, bone mineral density is reduced, bone microarchitecture is disrupted, and the amount and variety of non-collagenous proteins in bone is altered. The World Health Organization (WHO) defines osteoporosis (in women) as a bone mineral density 2.5 standard deviations below peak bone mass (versus an average 30-year-old healthy female). Osteoporosis is most common in women after menopause, where it is called postmenopausal osteoporosis, but may also develop in men, and may occur in anyone in the presence of particular hormonal disorders and other chronic diseases or as a result of medications (e.g., glucocorticoids) where the disease is called steroid- or glucocorticoid-induced osteoporosis, and as a result of nutritional deficiency states or other metabolic disorders, including, but not limited to, hyponatremia or as a secondary consequence of cancer. Given its influence on the risk of fragility fracture, osteoporosis may significantly affect life expectancy and quality of life. About 20 percent of senior citizens who suffer a hip fracture die within a year of fracture. About 20 percent of individuals with a hip fracture end up in a nursing home within a year. Hip fractures account for 300,000 hospitalizations each year. The direct care costs for osteoporotic fractures alone are already up to $18 billion each year. That number is expected to increase if action to prevent osteoporosis is not taken now. With healthy nutrition, physical activity every day, and regular medical check-ups and screenings, people of all ages can have strong bones and live longer, healthier lives. Therefore, reduced incidence of osteoporosis is a possible outcome of adequate theobromine supply to a person in need thereof. One embodiment of the present disclosure provides compositions and methods for treating osteoporosis, said compositions comprising theobromine.
- Any biologically acceptable dosage forms, and combinations thereof, are contemplated by the inventive subject matter. Examples of such dosage forms include, without limitation, chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi-layer tablets, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, beads, powders, granules, particles, microparticles, dispersible granules, cachets, douches, suppositories, creams, topicals, inhalants, aerosol inhalants, patches, particle inhalants, implants, depot implants, ingestibles, injectables, infusions, health bars, confections, cereals, cereal coatings, foods, nutritive foods, functional foods, dental varnish, and combinations thereof. For example, a theobromine varnish (a concentrated form of theobromine for application to the surface, the enamel, the dentine, and or cementum of at least one tooth) may provide topical theobromine therapy to a person in need thereof to, for example and without limitation, help prevent decay, remineralize the tooth surface, and treat dentine hypersensitivity. The preparations of the above dosage forms are well known to persons of ordinary skill in the art.
- Preferably, foods enriched with theobromine are selected from the group including:
- baked goods and mixes (e.g., bread); chewing gum; breakfast cereals; cheese products; nuts and nut products; gelatins, pudding, custard, and fillings; frozen dairy products; milk products (e.g., meal-replacement beverages, yogurt, yogurt drinks); dairy product analogs; hard candy; soft candy; soups and soup mixes; snack foods; beverages; processed fruit juice; fruit smoothies; powdered fruit-flavored drinks; processed vegetable juice; sports or isotonic drinks; meal-replacement beverages; non-milk-based beverages (e.g., soy milk); bottled water (e.g., vitamin, enhanced, and bottled waters); coffee; tea; fats and oils; fish products; plant protein products; poultry products; and meat products;
- more preferably, baked goods and mixes; breakfast cereals; gelatins, puddings, and fillings; dairy product analogs; soups and soup mixes; poultry products; nuts and nut products; frozen dairy;
- milk products; soft candy; plant protein products; fats and oils;
- more preferably, nuts and nut products; frozen dairy; milk products; soft candy; plant protein products; fats and oils; and
- more preferably nuts and nut-based products; milk products; soft candy. A further summary is provided in TABLE 2.
-
TABLE 2 Summary of Individual Proposed Food-Uses and Use-Levels for Theobromine Serving Use Theobromine Size Level Food Category Proposed Food Use (mg/serving) (g or mL) (%) Baked Goods & Baking Bread 15 25 0.060 Mixes Breakfast Cereals Instant or Regular 30 37 0.13 Oatmeal Ready-to-Eat Cereals 30 30 0.10 Beverages & Beverage Sports & Isotonic Drinks 60 488 0.012 Bases Meal-Replacement 75 240 0.017 Beverages, Non Milk-Based Chewing Gum Chewing Gum 10 3 0.33 Coffee/ Tea Tea 40 488 0.0082 Dairy Product Analogs Soy Mil 40 250 0.016 Gelatins, Puddings, & Gelatin 40 85 0.047 Custard Hard Candy Mints 5 2 0.25 Milk Products Meal-Replacement 75 240 0.031 Beverages, Milk-Based Yogurt (fresh, not 50 170 0.029 chocolate) Yogurt Drinks 25 28 0.089 Processed Fruits & Fruit Smoothies 50 366 0.014 Fruit Juices Powdered Fruit-Flavored 50 8 0.62 Drinks - The supplement is preferably administered during one or more of the three stages of pregnancy: preconception, pregnancy, and during lactation/postpartum. Preferably, the supplement is administered during preconception, pregnancy, and during lactation/postpartum. Preferably, the maternal supplement is administered during preconception and during pregnancy and during lactation/postpartum. Preferably, the maternal supplement is administered during lactation/postpartum.
- In accordance with another embodiment of the present invention, a surgical bone defect filling product comprising theobromine is provided. More specifically, the surgical bone defect filling product comprises theobromine and allograft bone. The surgical bone defect filling product may further comprise gelatin, with the gelatin being cross linked by lyophilization of the composition to form a solid composition which is later rehydrated for application to a bone defect area. The surgical bone defect filling product may be a shaped osteoimplant, meaning a predetermined or regular form or configuration in contrast to an indeterminate or vague form or configuration and by way of example would be characteristic to a wedge, cylinder, disk, plate sheet, tube and the like. The surgical bone defect filling product may comprise partially demineralized bone material (e.g., having a residual calcium content ranging between about 3 to about 10%, preferably 4 to 6%). Methods of manufacturing suitable demineralized bone material are known to those of ordinary skill in the art and discussed, for example, in WO 2007/133722, which is incorporated by reference herein.
- In accordance with another embodiment of the present invention, a sterile malleable bone composition for application to a bone defect site to promote new bone growth at the site comprising theobromine and demineralized osteogenic bone powder with a particle size ranging from about 250 to about 750 microns is provided. In another embodiment, the composition comprises theobromine and demineralized osteogenic bone particles with a particle size ranging from about 0.1 to about 5 mm, from about 0.1 to about 4 mm, from about 0.1 to about 3 mm, from about 0.1 to about 2 mm, and from about 0.1 to about 1 mm.
- Fetal calvaria cells were cultured in 24-well culture plates using D-MEM and supplemented with 10% (V/V) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were cultured in medium with various concentrations (0.1, 1.0, 10, 20, 40, 60, and 100 μM) of theobromine and without theobromine (control) for 96 hours, then counted using trypan blue dye exclusion method after culture. The results are shown below in TABLE 3.
-
TABLE 3 Theobromine (μM) Cells/well (×103) % vs. control 0 72.58 100 0.1 56.53 78 1.0 82.96 114 10 75.64 104 20 82.18 113 40 63.96 88 60 56.04 77 100 43.42 60 - The data of TABLE 3 demonstrate a slight increase in cell proliferation at theobromine concentrations between 1.0 and 20 μM.
- UMR 106-01 rat obsteoblast-like cells were cultured in 24-well culture plates using D-MEM supplemented with 10% (V/V) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were cultured in medium with various concentrations (0.0027. 0.027, 0.27, 2.7, 27, and 270 μM) of theobromine and without theobromine (control) for 96 hours, then counted using trypan blue dye exclusion method. The results are shown in TABLE 4. Statistical analysis was done using Student's t-test. P-values less than 5% were considered statistically significant.
-
TABLE 4 Theobromine Cell Number/mL (μM) Mean ± SEM (×104) % change p- value 0 101.50 ± 2.84 0 — 0.0027 112.50 ± 7.38 14 0.19 0.027 129.00 ± 6.05 27 0.002 0.27 126.50 ± 5.04 26 0.002 2.7 121.00 3.35 20 0.001 27 120.50 ± 7.07 20 0.008 270 134.50 ± 7.88 33 0.003 - The data of TABLE 4 demonstrate a significant increase in proliferation of osteoblast-like cells at theobromine concentrations between 0.027 and 270 μM. These results stand in contrast with prior art results demonstrating that caffeine (1,3,7-trimethylxanthine, with one more methyl group—at the 1 position—than theobromine) inhibits cell proliferation (Kamagata-Kiyoura, Y., Ohta, M., Cheuk, G., Yazdani, M., Saltzman, M. J. and Nakamoto, T. Combined effects of caffeine and prostaglandin E2 on the proliferation of osteoblast-like cells (UMR 106-01). J. Periodontol. 1999; 70:283-288).
- Animals: Ten pregnant Sprague Dawley rats were ordered from Harlan Laboratories and shipped as soon as pregnancy was confirmed(day 1).
- Prenatal: Beginning on
day 7, a specially prepared diet comprising theobromine (Thb) powder was fed to the experimental group (5 female rats) and control group without Thb (5 female rats). The Thb dose was approximately 1 mg per 100 g body mass in food. To prevent the need for constant weighing of pregnant and nursing animals, the average weight during pregnancy and the average food intake was approximated. Approximations were based on the study sponsor's prior experience, data from Harlan laboratories, and data from Keenan et al. “The Effects of Overfeeding and Dietary Restriction on Sprague-Dawley Rat Survival and Early Pathology Biomarkers of Aging” Toxicol Pathol. 1994; 22:300. To attain approximately 1 mg of Thb per 100 g body mass, the test diet consisted of 113 mg of finely ground Thb powder mixed well with 1 kg of powdered chow. Birth was predicted to occur during the afternoon ofday 22 or early morning ofday 23. Postnatal theobromine doses were as follows: 88 mg/kg forpostnatal days 1 to 14; 59 mg/kg forpostnatal days 14 to 22. After weaning, theobromine was added to the diet of offspring as follows: 89 mg/kg forpostnatal days 22 to 29; 42 mg/kg for postnatal days 29 to 50. These concentrations in the diet were calculated to provide about 1 mg/100 gram of body weight of theobromine per day, based on total food intake. Only female pups were used for data acquisition. Male pups were either humanely euthanized by lethal injection or transferred to another protocol. In some instances, males were used to normalize suckling litter sizes. - Postnatal: Sixteen female pups per group were required for analysis, but up to 40 were utilized due to leveling of litter sizes. To minimize maternally-introduced variance during nursing, equal numbers of female neonates derived from each litter were randomized and re-allocated to each of the mothers. The appropriate diet (Thb or control) was continuously fed to the postnatal mothers. Thus, postnatal mothers fed Thb provided Thb via milk to nursing pups during the nursing interval. Pups were marked via tail tattoo or ear punch to maintain identity with offspring and dam.
- Weaning: Pups were weaned 22 days after birth, when they became independent. The experimental group received theobromine in the diet continuously, until
day 50, as described above. - Euthanasia: fifty days after birth, half of the pups in each group were humanely euthanized by intraperitoneal injection of pentobarbital (100 mg/kg), CO2 inhalation, or inhalation overdose of isoflurane. These methods are acceptable under the guidelines of the American Veterinary Medical Association. Shortly after death was confirmed, left hindlimbs with intact femoral head were dissected from the pelvis and placed in phosphate buffered formalin for biomechanical testing. Right femurs were cut at the condyles with rongeurs, and the marrow flushed into alpha minimal essential medium (α-MEM) containing penicillin, streptomycin and amphotericin B with 2% bovine serum. Marrow cells, preserved on wet ice in sterile media, were shipped via courier to the Institute for Regenerative Medicine for analysis.
- Theobromine (Thb): Thb was prepared as 100×-1000× aliquots on water by warming at 60° C. for 15 min prior to centrifugation at 2500 g for 15 min. Because the solubility of Thb in water is frequently incomplete and unstable at the concentrations required for generation of stock solutions, spectrophotometry at 260 nm was used to confirm concentration of stocks. With warming, it was possible solubilize about 500 mg in 50 mL of water, which is close to the published solubility in the Merck index. It was noted that storage at 4° C. caused solubility to drop substantially, necessitating re-solubilization at each media replenishment.
- Initially, 0, 1 and 10 μmol/mL (0.180-1.80 μg/mL) of theobromine (Thb) were used in hMSC differentiation assays in a carrier comprised of 10 mM NH4OH. For the current assays, cells were tested with 1-500 μmol/mL (0.18-90 μg/mL). The volume of carrier (NH4OH) necessary to attain these concentrations did not affect the pH of the culture, but substantially inhibited osteogenic differentiation. Thus, although the solubility of Thb in water is about half that of an alkaline carrier, water was used water as a carrier because the amount of water that can be added to hMSC cultures is much higher.
- Water solutions of Thb are unstable until diluted to a working concentration. The extinction coefficient of Thb in H2O was calculated at 260 nm and stock solutions screened after warming to confirm the amounts added to the cells. With this protocol, a maximum of 100 μg/mL was added to media.
- General MSC Protocol: For hMSCs, bone marrow cells were recovered and supplied by the Tulane adult stem cell distribution facility, New Orleans, Louisiana in accordance with Institutional Review Board approval. Nucleated cells were recovered from the bone marrow by discontinuous density gradient centrifugation using Ficoll Paque (AP Biotech, Piscataway, N.J.). Plastic adherent, nucleated cells were separated from the aspirate by culturing in α-MEM (Gibco, Invitrogen, Carlsbad, Calif.) containing 20% (v/v) fetal calf serum (FCS; Atlanta Biochemical, Norcross, Ga.), 100 μg/mL streptomycin, 100 U/mL penicillin, and 2 mM glutamine (Gibco, Invitrogen). After 14 days in culture, adherent cells were recovered from the monolayer by incubation with 0.25% (w/v) trypsin and 1 mM EDTA (Fisher Lifesciences; Pittsburgh, Pa.) for 5 to 7 min at 37° C. and re-plated at a density of 100 cells/cm2. The cells were cultured with changes of media every 2 to 3 days. At semi-confluency, 107 cells were frozen at −180° C. in ten 1 mL aliquots containing α-MEM, 50% (v/v) FCS and 2% DMSO (Fisher).
- Alkaline Phosphatase (ALP) and Osteoprotegerin (OPG) Assays: Osteoblastogenesis was induced on confluent monolayers in 6-24 well plates by addition of complete culture medium supplemented with 5 mM sodium glycerophosphate, 50 μg/mL L-ascorbate. Thb was added to the conditions where appropriate. Medium was changed every 48 hours. After 5-10 days, ALP activity in the monolayers was measured as follows. The cells were washed once with PBS, then with 100 mM Tris HCl (pH 9.0) containing 100 mM KCl and 1 mM MgCl2 (ALP buffer). After washing, 1.5 mL of a 1:2 solution of para-nitrophenylphosphate (pNPP; Fisher) and ALP buffer was added to the wells to produce a 5 mm path length between the bottom of the well and the meniscus. ALP activity as a function of pNPP metabolism (ΔOD405/min) was measured using a temperature-controlled automated plate reader (FluoStar, BMG Biotech, Chicago, Ill.). The rates were compared against standards with a known concentration of ALP and normalized against cell number. OPG ELISAs (antibody set from R and D Systems) were performed on conditioned media from these assays.
- Cell Number: Cells were recovered by trypsinization, then the number of cells per well was measured by nucleic acid fluorescence incorporation assay. The cells were added to 2× CyQuant dye solution (Molecular Probes Incorporated; Eugene, Oreg.). Nucleic acid intercalation-induced fluorescence was measured using a microplate fluorescence reader (FLX800; Bio-Tek Instruments Incorporated; Winooski, Vt.) set to 480 nm excitation and 520 nm emission. The degree of fluorescence was directly proportional to cell number when compared against known standards.
- Transcriptome Analysis: Total RNA from 1×106 cells was isolated using an RNA isolation kit (High Pure, Roche, Nutley, N.J.) and used to synthesize double-stranded cDNA (Superscript Choice System; Invitrogen). Biotin-labelled cRNA (GeneChip In Vitro Trancription labeling Kit; Affymetrix, Santa Clara, Calif.) was transcribed, then cleaned (RNAeasy Mini Kit; Qiagen, Valencia, Calif.), fragmented, and hybridized on HG-U133 Plus 2.0 microarray chips (Affymetrix). After washing, microarray chips were stained with streptavidin-phycoerythrin (Invitrogen), amplified with biotinylated anti-streptavidin (Vector Laboratories, Burlingame, Calif.), stained with streptavidin-phycoerythrin, then scanned (GeneChip Scanner 3000, Affymetrix) using GeneChip Operating software 1.0 (GCOS, Affymetrix). Data were analyzed using dChip software. Expression levels (as functions of arbitrary densitometric values from the array scans) were used to generate lists of upregulated genes (at least 2-fold). Lists of upregulated genes were used to interrogate the tissue expression and gene ontology databases on the DAVID website run by the National Institute of Allergy and Infectious Diseases (NIAID), NIH (available at: david.abcc.ncifcrf.gov). For tissue expression analyses, the databases are comprised of clusters of genes that are highly expressed in given tissues (this comes from a consolidation of all of the human genome/expression data from the US, Europe and Japan). The groups vary substantially in size (e.g., the brain group is 10 times larger than the bone group) so enrichment is scored by proportions of the lists rather than the absolute number of genes that correspond with each list. The database then assigns a p-value which represents the probability that the experimental gene list (e.g., hMSCs treated with Thb) has a given proportion of tissue specific genes due entirely to chance. Such p-values become quite small because the process involves hundreds or even thousands of transcripts.
- Preliminary Biochemical Assays on hMSCs: To define dosage and duration of treatment, confluent cultures of hMSCs (2 donors) were exposed to osteogenic supplements in the presence of various doses of Thb. After 5-10 days, a measurement of ALP activity or OPG secretion was carried out on the monolayers. The early osteogenic markers were upregulated by Thb in a dose dependent, biphasic manner that reached maximum effect at 100 μM Thb (
FIGS. 1A & 1B ). The magnitude of the increase was detectable after 4 days, but was most prominent after 8 days of exposure (data not shown). Slight cell loss was also evident at high doses, but was marginal in most cases (FIG. 1C ). To further investigate the effect of Thb on osteogenic marker expression, and to finalize dosage for microarray analysis, three more hMSC donors were assayed. As previously observed, increased ALP activity was evident when cells were treated with 10-100 μM Thb for 8 days (FIG. 2 ). - Microarray Analyses on Thb-Treated hMSCs: Large scale cultures of hMSCs were prepared and exposed to 0, 25, 50 and 100 μM Thb for 8 days in conditions identical to those employed for the ALP and OPG assays described above. Total RNA was extracted from the cultures and subjected to microarray analysis. The following transcriptomic comparisons were made for each donor: 0 vs. 25, 0 vs. 50, 0 vs. 100 μM Thb. Those genes with more than 2-fold upregulation when compared to controls were listed. Upon examination of the data, it was apparent that although there was some inter-donor variation, the doses only cause fluctuations on fold changes rather than the identity of the genes in the list. The dose response effect confirmed that the data were robust. Given that the doses of Thb did not affect the identity of the genes in the lists, the 0 vs. 50 μM Thb gene lists were employed for database interrogation.
- The first set of analyses were designed to address the hypothesis “Is there a statistically significant upregulation of genes commonly related to osteogenesis in hMSCs exposed to Thb?” For this purpose, the upregulated gene lists were compared to tissue expression databases using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 database handler maintained by the National Institute of Allergy and Infectious Diseases (NIAID), NIH (available at david.abcc.ncifcrf.gov). For two donors tested, “bone gene” enrichment is in the top 3.5% of statistically significant tissue expression signatures (
FIG. 3 ,donor 281; andFIG. 4 , donor 7023), and this represented the first or second on the list. Fordonor 7057, the bone signature was in the top 9% of the list, but the overall list was longer. The variation in the size of the lists for each hMSC preparation indicates that the different cell lines exhibit different degrees of plasticity and in maximally multipotential cells, the effects of Thb seem to be pleiotropic (e.g., in 7057), whereas in hMSCs with less pluripotency bone is by far the preferred path (e.g.,donors 281 and 7023). This is quite normal, since hMSCs from different donors exhibit donor-dependent variability depending on donor age, sex, degree of expansion, culture conditions etc. Nevertheless, even in profoundly pluripotent hMSC lines, bone is high on the list. - To investigate possible mechanisms of action, the lists of Thb upregulated genes were then used to probe the signal transduction pathway database to test whether Thb had a preferential molecular mode of action. There were few hits, suggesting that Thb may transduce its action through a novel pathway. Nevertheless, extracellular matrix and focal adhesion signaling pathways were significantly represented in
donors 281 and 7023 (those with a highly significant osteoblast signature). ECM interations and focal adhesion signaling are generally mediated through collagen-integrin mediated pathways via PI3 kinase (seeFIGS. 7 & 8 ). It is therefore possible that Thb causes a feed-forward loop through upregulation of collagen, integrin and PI3 kinase signaling. - The mechanical properties of femurs obtained from EXAMPLE 3 were studied at the university of Texas using protocols described by Beary (Beary D F. The effect of fluoride and low calcium on the physical properties of the rat femur. Anat. Rec. 1969; 164:305-316). Compared to the Beary study, however, the instant measurements were calculated automatically via computer attached to the measurement apparatus.
- Briefly, an Instron Universal Testing Instrument was employed to test the femurs of EXAMPLE 3 for strength and flexibility. A special metal holding device for the femurs was used so that the diaphysis was loaded anteriorly at the midpoint The force, F, was applied midway between these supports on the anterior surface. The load at the elastic limit, maximum load, and load at the breaking point were measured on the x-axis, and the amounts of deflection at these loads were measured on the y axis. In the mechnical properties study, note that the length of the portion of each specimen that was used to make the measurement is the same, 15 mm, for all. This length is defined by the distance between the two supports at each end of the specimen, as it is placed under a load at the center, and bent until it breaks. This is called a three-point bending measurement, and produces transverse strength results. It is also known as flexure strength. UTS=ultimate transverse strength. Data from femurs of theobromine-treated rats are provided in TABLES 5.1 and 5.2, while the study parameters are provided in TABLES 5.3 and 5.4. Data from femurs of control rats are provided in TABLES 6.1 and 6.2, while the study parameters are provided in TABLES 6.3 and 6.4.
-
TABLE 5.1 Energy U Trans- Strain Spec- Thick- To Peak verse Mod- at imen Width ness Break Load Strength ulus Break # mm mm N*mm N MPa MPa mm/ mm 1 3.52 3.01 40.630 70.87 63.334 1987.32 0.0458 2 4.20 2.78 25.079 71.85 63.083 3112.30 0.0255 3 4.10 2.70 32.354 75.68 72.166 3815.56 0.0279 4 3.75 2.70 28.230 56.81 59.230 3341.43 0.0329 5 3.58 2.72 25.997 56.30 60.584 2927.70 0.0321 6 4.10 2.80 37.889 72.24 64.048 3510.26 0.0336 7 3.80 2.80 26.185 62.43 59.722 3123.06 0.0295 8 3.79 2.78 21.103 54.69 53.210 2715.69 0.0280 9 3.79 2.78 22.884 65.09 63.332 3394.93 0.0258 10 3.79 2.78 24.809 67.36 65.543 3685.32 0.0259 Mean 3.84 2.78 28.516 65.33 62.425 3161.36 0.0307 Std. 0.22 0.09 6.441 7.51 4.889 531.95 0.0061 Dev. -
TABLE 5.2 Spec- Stress At Energy to Strain At Ext At imen Offset Offset Yield Yield Offset Yield Break # Yield Yield MPa N*mm Index mm/ mm mm 1 340 30.420 6.529 340 0.0156 1.735 2 290 50.251 11.870 290 0.0163 1.162 3 266 57.176 12.150 266 0.0152 1.162 4 82 39.791 5.349 82 0.0122 0.732 5 197 35.110 4.971 197 0.0122 1.092 6 221 45.720 8.358 221 0.0133 1.168 7 176 36.320 5.344 176 0.0118 0.960 8 241 33.625 5.295 241 0.0126 1.130 9 201 43.236 6.945 201 0.0130 0.940 10 282 49.833 8.335 282 0.0138 1.193 Mean 230 42.148 7.515 230 0.0136 1.128 Std. 72 8.588 2.665 72 0.0016 0.258 Dev. -
TABLE 5.3 Calculation Inputs: Name Value Units Break Marker Drop 50.0 % Break Marker Elongation 2.540 mm Slack Pre-Load 4.448 N Slope Segment Length 25.000 % Span 19.000 mm Strain Point 1 0.05 mm/ mm Strain Point 2 0.020 mm/ mm Strain Point 3 0.020 mm/mm Yield Angle 0.000 rad Yield Offset 0.020 % Yield Segment Length 2.0 % -
TABLE 5.4 Test Inputs: Name Value Units Break Sensitivity 90 % Break Threshold 5.000 N DataAcqRate 10.0 Hz Extension Endpoint 25.400 mm Initial Speed 2.0 mm/min Load Endpoint 4448 N Outer Loop Rate 100 Hz Slowdown Extension 0.000 mm Slowdown Load 0.000 N Slowdown Strain 0.000 mm/mm Strain Endpoint 0.100 mm/mm -
TABLE 6.1 Energy U Trans- Flexural Strain Spec- Thick- To Peak verse Mod- at imen Width ness Break Load Strength ulus Break # mm mm N*mm N MPa MPa mm/ mm 1 3.56 2.78 22.425 68.39 70.845 3853.28 0.0241 2 3.74 2.80 23.743 61.63 59.899 3115.08 0.0275 3 3.74 2.71 33.432 59.57 61.808 3132.35 0.0357 4 3.45 2.71 31.500 64.41 72.445 3772.38 0.0309 5 3.52 2.60 27.890 56.25 67.373 4259.04 0.0301 6 3.65 2.78 24.838 67.30 67.995 3826.32 0.0253 7 3.50 2.61 16.902 55.33 66.138 3363.08 0.0226 8 3.20 2.78 22.344 66.56 76.704 3577.97 0.0255 9 3.90 2.78 24.778 70.68 66.834 3442.42 0.0257 10 3.52 2.60 24.530 61.29 73.413 3026.66 0.0294 Mean 3.58 2.72 25.238 63.14 68.346 3536.86 0.0277 Std. 0.19 0.08 4.741 5.19 5.174 394.91 0.0039 Dev. -
TABLE 6.2 Name Value Units Break Marker Drop 50.0 % Break Marker Elongation 2.540 mm Slack Pre-Load 4.448 N Slope Segment Length 25.000 % Span 19.000 mm Strain Point 1 0.05 mm/ mm Strain Point 2 0.020 mm/ mm Strain Point 3 0.020 mm/mm Yield Angle 0.000 rad Yield Offset 0.020 % Yield Segment Length 2.0 % -
TABLE 6.3 Calculation Inputs: Spec- Stress At Energy to Strain At Ext At imen Offset Offset Yield Yield Yield Offset Yield Break # Yield MPa N*mm Index mm/ mm mm 1 270 52.824 8.728 270 0.0139 1.110 2 248 42.502 7.403 248 0.0139 1.110 3 236 44.350 7.829 236 0.0144 1.250 4 304 64.991 13.120 304 0.0174 1.300 5 195 46.130 5.435 195 0.0111 1.080 6 300 53.524 10.001 300 0.0142 1.228 7 222 53.334 9.224 222 0.0161 0.880 8 249 68.004 13.691 249 0.0193 0.955 9 265 47.221 8.980 265 0.0139 1.128 10 158 52.823 9.761 158 0.0177 0.790 Mean 245 52.570 9.417 245 0.0152 1.083 Std. 46 8.387 2.483 46 0.0024 0.164 Dev. -
TABLE 6.4 Test Inputs: Name Value Units Break Sensitivity 90 % Break Threshold 5.000 N DataAcqRate 10.0 Hz Extension Endpoint 25.400 mm Initial Speed 2.0 mm/min Load Endpoint 4448 N Outer Loop Rate 100 Hz Slowdown Extension 0.000 mm Slowdown Load 0.000 N Slowdown Strain 0.000 mm/mm Strain Endpoint 0.100 mm/mm - As shown by the data of TABLES 5.1, 5.2, 6.1, and 6.2, sample width and thickness were significantly greater in the theobromine group compared to controls. Femur length was also significantly greater in the theobromine group, compared to controls.
- U transverse strength (bending) in the theobromine group (62.4252 MPa) was significantly less than the control group (68.3454 MPa).
- Modulus (stiffness/rigidity) the theobromine group (3161.36) was not significantly different from that of the control group (3536.858). This result may be due to the mean cross-section of the treated group being numerically greater than that of the control group (cross-section is shown by width and thickness measurements). Consequently, a numerically greater amount of energy was required to break the bones of the treated group compared to those of the control group: Energy to break in the treated was 28.516, whereas the control was 25.238. Strength and modulus factor were measured in the cross-sectional area, so they are normalized values.
- If theobromine treatment made the bones larger in cross-section, but not inherently stronger, it would take more force to break the larger (in cross-section) treated bones than the smaller control bones (as measured by peak load). But dividing a larger peak load by a larger cross-sectional area makes the modulus and strength smaller in the treated group (but statistically no different). Peak load of treated group was 65.33, whereas the control group was 63.14.
- There is a trend toward greater resistance to breaking in the treated group, as shown by more force (higher peak load) being required to break the bones in the treated group. Therefore, the data indicate that femurs from theobromine-treated rats are more resilient or robust than those of control rats.
-
FIG. 9A shows the weight (grams) of rat pups in the study of EXAMPLE 3 at the days indicated. The three right-most columns indicate the weight over time of theobromine-treated rats, while the three left-most columns indicate the weight over time of the control rats. -
FIG. 9B shows the weight (grams) of the rat pups in the study of EXAMPLE 3 atday 40. Atday 40, body weight of theobromine group was significantly greater than that of the control group. At day 47 (data not shown), the mean weight of the theobromine group was about 171 g, whereas for the control group it was about 160 g. - Bone data of
FIGS. 9C, 9D, 9E, 9F, 9G, and 9H were obtained by utilizing high resolution micro-computer aided tomography to evaluate bone quality. -
FIG. 9C shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating the number of trabeculae of control and theobromine-treated rats. These data reflect the formation of bone, and demonstrate significantly more bone formation in theobromine-treated rats, versus controls. -
FIG. 9D shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating trabecular bone spacing. Significantly less spacing between the trabecular bone was observed in the theobromine-treated group compared to the control group, suggesting greater trabecular bone formation in the theobromine-treated rats. This is a very important aspect of bone formation by feeding theobromine. -
FIG. 9E shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating trabecular bone thickness. No significant difference was observed between the theobromine-treated group and the control group, but these data do not indicate whether density within the hard tissue is different or not. -
FIG. 9F shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating the percent volume of trabecular bone. Although the difference between the theobromine-treated group and the control group is not statistically significant, the theobromine-treated group was slightly elevated over the control group. -
FIG. 9G shows data obtained from femurs of rat pups from EXAMPLE 3, demonstrating bone area at the midshaft of each femur. The trabecular bone area of femurs from the theobromine-treated group was significantly greater (indicating thicker bone) than that of the control group. -
FIG. 9H shows data obtained from proximal tibia of rat pups from EXAMPLE 3, demonstrating trabecular bone area. The trabecular bone area of proximal tibia of theobromine-treated rats was significantly greater (indicating thicker bone) than that of the control group. - The data of
FIGS. 9A, 9B, 9C, 9D, 9E, 9F, 9G, and 9H , demonstrate that ingestion of theobromine during growth enhances body weight over time (FIGS. 9A & 9B ), enhances bone formation overall (FIG. 9C ), especially trabecular bone formation (FIG. 9D ), and enhances bone area (FIGS. 9G & 9H ). - All references cited in this specification are herein incorporated by reference as though each reference was specifically and individually indicated to be incorporated by reference. The citation of any reference is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such reference by virtue of prior invention.
- It will be understood that each of the elements described above, or two or more together may also find a useful application in other types of methods differing from the type described above. Without further analysis, the foregoing will so fully reveal the gist of the present disclosure that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this disclosure set forth in the appended claims. The foregoing embodiments are presented by way of example only; the scope of the present disclosure is to be limited only by the following claims.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/908,373 US20180325906A1 (en) | 2013-03-15 | 2018-02-28 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792425P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/027018 WO2014152158A1 (en) | 2013-03-15 | 2014-03-14 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
US201514775104A | 2015-09-11 | 2015-09-11 | |
US15/908,373 US20180325906A1 (en) | 2013-03-15 | 2018-02-28 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/027018 Division WO2014152158A1 (en) | 2013-03-15 | 2014-03-14 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
US14/775,104 Division US9937184B2 (en) | 2013-03-15 | 2014-03-14 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180325906A1 true US20180325906A1 (en) | 2018-11-15 |
Family
ID=51581132
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/775,104 Active US9937184B2 (en) | 2013-03-15 | 2014-03-14 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
US15/908,373 Abandoned US20180325906A1 (en) | 2013-03-15 | 2018-02-28 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/775,104 Active US9937184B2 (en) | 2013-03-15 | 2014-03-14 | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
Country Status (16)
Country | Link |
---|---|
US (2) | US9937184B2 (en) |
EP (2) | EP2970888A4 (en) |
JP (2) | JP6591958B2 (en) |
KR (1) | KR20150132434A (en) |
CN (1) | CN105189736A (en) |
AR (1) | AR095471A1 (en) |
AU (1) | AU2014240064A1 (en) |
BR (1) | BR112015022471A2 (en) |
CA (1) | CA2904639A1 (en) |
EA (1) | EA201591481A1 (en) |
HK (2) | HK1219110A1 (en) |
IL (1) | IL241303A0 (en) |
MX (1) | MX2015013241A (en) |
SG (1) | SG11201507445VA (en) |
TW (1) | TW201521729A (en) |
WO (1) | WO2014152158A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010014931A1 (en) * | 1998-05-27 | 2001-08-16 | Robert Aglietti | Cache management for a multi-threaded processor |
US20010014831A1 (en) * | 1998-12-14 | 2001-08-16 | Scarborough Nelson L. | Bone graft, method of making bone graft and guided bone regeneration method |
WO2011100671A2 (en) * | 2010-02-12 | 2011-08-18 | Theocorp Holding Co., Llc | Methods and compositions to improve mechanical resistance of teeth |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290558A (en) * | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
JP3219881B2 (en) * | 1992-12-25 | 2001-10-15 | サンスター株式会社 | Hair restorer |
GB2294879A (en) | 1994-10-19 | 1996-05-15 | Merck & Co Inc | Cylcooxygenase-2 Inhibitors |
US6183711B1 (en) | 1995-12-27 | 2001-02-06 | Tetsuo Nakamoto | Apatite-forming-systems: methods and products |
US6458375B1 (en) | 1998-02-27 | 2002-10-01 | Musculoskeletal Transplant Foundation | Malleable paste with allograft bone reinforcement for filling bone defects |
JP4426674B2 (en) * | 1999-09-01 | 2010-03-03 | 株式会社ロッテ | Bone resorption inhibitor |
KR20030032484A (en) * | 2001-10-18 | 2003-04-26 | 롯데제과주식회사 | Theobromine with Antitumor effects |
PL376821A1 (en) * | 2002-03-27 | 2006-01-09 | Immunex Corporation | Methods for increasing polypeptide production |
US20060204544A1 (en) | 2002-05-20 | 2006-09-14 | Musculoskeletal Transplant Foundation | Allograft bone composition having a gelatin binder |
US7498040B2 (en) * | 2005-10-12 | 2009-03-03 | Lifenet Health | Compositions for repair of defects in osseous tissues, and methods of making the same |
AU2003262911A1 (en) * | 2002-08-29 | 2004-03-19 | Scios Inc. | Methods of promoting osteogenesis |
US7582309B2 (en) * | 2002-11-15 | 2009-09-01 | Etex Corporation | Cohesive demineralized bone compositions |
WO2007098484A2 (en) * | 2006-02-21 | 2007-08-30 | The Trustees Of Princeton University | High-yield activation of polymer surfaces for covalent attachment of molecules |
US20110269717A1 (en) * | 2006-07-17 | 2011-11-03 | Braincells Inc. | Neurogenesis by modulating angiotensin |
EP2172113B1 (en) * | 2008-09-29 | 2014-03-19 | Maria Ascension Fernandez Jimenez | Functional and nutritional food product containing chocolate |
CN101715912B (en) * | 2008-12-02 | 2013-04-24 | 天津天狮生物发展有限公司 | Calcium chewable tablets and manufacturing process thereof |
CN103476440B (en) * | 2011-02-25 | 2016-10-19 | 新特斯有限责任公司 | Promote implant and the method for induction of bone growth of skeletonization |
-
2014
- 2014-03-14 EP EP14770277.3A patent/EP2970888A4/en not_active Withdrawn
- 2014-03-14 CN CN201480025405.9A patent/CN105189736A/en active Pending
- 2014-03-14 US US14/775,104 patent/US9937184B2/en active Active
- 2014-03-14 KR KR1020157029343A patent/KR20150132434A/en not_active Application Discontinuation
- 2014-03-14 TW TW103109638A patent/TW201521729A/en unknown
- 2014-03-14 CA CA2904639A patent/CA2904639A1/en not_active Abandoned
- 2014-03-14 AR ARP140101074A patent/AR095471A1/en unknown
- 2014-03-14 AU AU2014240064A patent/AU2014240064A1/en not_active Abandoned
- 2014-03-14 EP EP17206660.7A patent/EP3311819A1/en not_active Withdrawn
- 2014-03-14 SG SG11201507445VA patent/SG11201507445VA/en unknown
- 2014-03-14 MX MX2015013241A patent/MX2015013241A/en unknown
- 2014-03-14 BR BR112015022471A patent/BR112015022471A2/en not_active IP Right Cessation
- 2014-03-14 WO PCT/US2014/027018 patent/WO2014152158A1/en active Application Filing
- 2014-03-14 EA EA201591481A patent/EA201591481A1/en unknown
- 2014-03-14 JP JP2016502310A patent/JP6591958B2/en active Active
-
2015
- 2015-09-08 IL IL241303A patent/IL241303A0/en unknown
-
2016
- 2016-06-20 HK HK16107066.6A patent/HK1219110A1/en unknown
-
2018
- 2018-02-28 US US15/908,373 patent/US20180325906A1/en not_active Abandoned
- 2018-09-14 HK HK18111840.9A patent/HK1252530A1/en unknown
-
2019
- 2019-04-16 JP JP2019077721A patent/JP2019131608A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010014931A1 (en) * | 1998-05-27 | 2001-08-16 | Robert Aglietti | Cache management for a multi-threaded processor |
US20010014831A1 (en) * | 1998-12-14 | 2001-08-16 | Scarborough Nelson L. | Bone graft, method of making bone graft and guided bone regeneration method |
WO2011100671A2 (en) * | 2010-02-12 | 2011-08-18 | Theocorp Holding Co., Llc | Methods and compositions to improve mechanical resistance of teeth |
US20130129641A1 (en) * | 2010-02-12 | 2013-05-23 | Theocorp Holding Co., Llc | Methods and compositions to improve mechanical resistance of teeth |
Also Published As
Publication number | Publication date |
---|---|
HK1252530A1 (en) | 2019-05-31 |
EP3311819A1 (en) | 2018-04-25 |
JP2019131608A (en) | 2019-08-08 |
BR112015022471A2 (en) | 2017-08-22 |
CA2904639A1 (en) | 2014-09-25 |
EP2970888A1 (en) | 2016-01-20 |
US20160030434A1 (en) | 2016-02-04 |
JP6591958B2 (en) | 2019-10-16 |
AR095471A1 (en) | 2015-10-21 |
US9937184B2 (en) | 2018-04-10 |
IL241303A0 (en) | 2015-11-30 |
KR20150132434A (en) | 2015-11-25 |
SG11201507445VA (en) | 2015-10-29 |
EP2970888A4 (en) | 2017-04-12 |
WO2014152158A1 (en) | 2014-09-25 |
EA201591481A1 (en) | 2016-02-29 |
MX2015013241A (en) | 2015-12-15 |
HK1219110A1 (en) | 2017-03-24 |
JP2016518115A (en) | 2016-06-23 |
CN105189736A (en) | 2015-12-23 |
TW201521729A (en) | 2015-06-16 |
AU2014240064A1 (en) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pedrera-Zamorano et al. | Effect of beer drinking on ultrasound bone mass in women | |
JP4637052B2 (en) | Bone mass enhancing composition containing pollen cargo as an active ingredient | |
JP2016106098A (en) | Compounds and methods for treating bone disorders and controlling weight | |
Duarte et al. | The effects of caffeine administration on the early stage of bone healing and bone density: A histometric study in rats | |
US20180325906A1 (en) | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties | |
JP2007291081A (en) | Composition having bone resorption inhibition-related effect | |
WO2008004118A2 (en) | Carthamus tinctoris plant extracts for treating osteoporosis and the extraction process thereof | |
EP3626728A1 (en) | Peptide for inhibiting bone resorption | |
Liu et al. | Site-specific characteristics of bone and progenitor cells in control and ovariectomized rats | |
WO2008084283A2 (en) | Andrographis paniculata plant extracts for treating osteoporosis and the extraction process thereof | |
KR102308505B1 (en) | COMPOSITION FOR TREATMENT OF SARCOPENIA OR OSTEOPOROSIS THROUGH THE MECHANISM OF PROMOTING MYOBLAST DIFFERENTIATION OR INHIBITING THE DIFFERENTIATION OF OSTEOCLAST COMPRISING Cyclo (L-phenylalanyl-L-proline) | |
CN107530305B (en) | Mucosal immune activator | |
JP7308329B1 (en) | Sarcopenia preventive or ameliorating agent containing GABA as an active ingredient | |
JP6639162B2 (en) | Antiallergic agent containing lotus root extract | |
JP7319611B2 (en) | Proliferation promoter for stem cells | |
KR20160023965A (en) | Pharmaceutical composition for muscle regeneration comprising ursolic acid and leucine | |
JP2005021087A (en) | Egg-derived bone-strengthening composition | |
AU2006345882A1 (en) | Citrus reticulata plant extracts for treating osteoporosis and the extraction process thereof | |
JP2007302600A (en) | Composition for improving bone metabolism derived from vegetable material of genus oryza and method for producing the same | |
WO2008007216A2 (en) | Psoralea corylifolia plant extracts for treating osteoporosis and the extraction process thereof | |
WO2008084282A2 (en) | Punica granatum plant extracts for treating osteoporosis and the extraction process thereof | |
JP2017086020A (en) | Agent for maintaining undifferentiated state of stem cell and agent for promoting proliferation thereof | |
WO2008007214A2 (en) | Glycyrrhiza glabra plant extracts for treating osteoporosis and the extraction process thereof | |
WO2017175625A1 (en) | Composition for regulating bone metabolism | |
JP2018030787A (en) | Agent for maintaining the undifferentiated state of stem cell and agent for promoting the proliferation of stem cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THEOCORP HOLDING COMPANY, LLC, LOUISIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SADEGHPOUR, ARMAN;NAKAMOTO, TETSUO;REEL/FRAME:045476/0866 Effective date: 20160510 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |